Top Markets
Coin of the day
Adagio Therapeutics, Inc. Adagio Therapeutics, Inc.

Adagio Therapeutics, Inc.

ADGI
Clasificación en acciones #16422
Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical firm, primarily... Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical firm, primarily focused on the discovery, development, and subsequent commercialization of antibody-based therapeutics designed to combat infectious diseases across the United States. Its most advanced product candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical trials. This antibody is being evaluated for both the treatment and prevention of coronavirus disease. Adagio Therapeutics also engages in strategic collaborations. It partners with Adimab, LLC to facilitate the discovery and optimization of novel proprietary antibodies. Furthermore, the company works with the Scripps Research Institute on research initiatives aimed at identifying vaccine candidates that could prevent, diagnose, or treat influenza and beta coronaviruses. Founded in 2020, Adagio Therapeutics maintains its headquarters in Waltham, Massachusetts.
Precio por acción
$4.64
Última sincronización: 2022-09-12
Capitalización bursátil
$293.43M
Cambio (1 día)
0.87%
Cambio (1 año)
0.00%
País
US
Comercio Adagio Therapeutics, Inc. (ADGI)

Categoría

Historial de desdoblamientos de acciones de Adagio Therapeutics, Inc. (ADGI)
La acción Adagio Therapeutics, Inc. (símbolo: ADGI) tuvo un total de 0 desdoblamientos.
El desdoblamiento más reciente ocurrió el Sep 02, 2026.
Una acción ADGI comprada antes de Sep 02, 2026 equivaldría hoy a 0 acciones ADGI.
Lista de desdoblamientos de acciones
Año Desdoblamiento Multiplicador Multiplicador acumulado
Not enough data for the provided dates.
Desdoblamientos de acciones de empresas similares o competidoras
Empresa Número de desdoblamientos de acciones Multiplicador acumulado País
1 x2
US
0 -
NL
0 -
US
1 x3
AU
0 -
CH